Pathogenetic significance of vascular endothelial growth factor in psoriasis
DOI:
https://doi.org/10.15587/2313-8416.2016.61155Keywords:
psoriasis vulgaris, pathogenesis, angiogenesis, vascular endothelial growth factor, clinical manifestationsAbstract
Recent studies have shown that psoriasis is related to angiogenesis-dependent diseases since the activation of T-lymphocytes leads to a marked expansion of the skin capillaries damaged skin. Vascular endothelial growth factor (VEGF) is one of the powerful promoter of angiogenesis.
The aim of the research was to study the VEGF level in the serum of patients with various manifestations of vulgaris plaques psoriasis.
Metods of research. We observed 35 patients with psoriasis at the age of 19–44 years. The clinical picture was characterized by limited (31.4 %) and dissemination (68.6 %) skin process, plaques rash, staying in the progressive (57.1 %) and stationary (42.9 %) stages. PASI ranged from 7.8 to 23.6 points (on average – 14.6±0.7 points). Patients with relapsed more than two times per year are dominated.
VEGF level was determined in the serum by ELISA. Statistical analysis of the results was performed using non-parametric methods and parametric statistics.
Results. VEGF revealed an increase in blood of patients with psoriasis 3.4–7.9 times (p<0.05) relative to the index in the control group. The degree of VEGF changes depended on the stage, the prevalence, severity and frequency of recurrence of the psoriasis.
Conclusions. VEGF levels in the blood increased significantly more in the advanced stage, when the process of propagation, severe and frequent relapses psoriasis (more than two times per year) compared to the same in the stationary phase, a limited process of mild to moderate severity, recurrences 1–2 times per year. Pathogenetic significance of the main angiogenic factors in psoriasis confirms the correlation between VEGF and the clinical manifestations of the disease
References
Bolotnaja, L. A. et. al; Bolotnaja, L. A. (Ed.) (2015). Prakticheskaja dermatologija. Kharkiv: S.A.M., 278.
Kondrat'eva, N. N., Rasskazov, Ja. A., Bakulev, A. L. (2013). Terapija bol'nyh psoriazom: sovremennyj vzgljad na problemu. Prakticheskaja medicina, 1-4 (13), 28–32.
Sprindzhuk, M. V. (2010). Angiogenez. Morfologіja, ІV (3), 4–13.
Canavese, M., Schauber, J. (2011). Vascular Endothelial Growth Factor and Psoriasis Pathogenesis: Major Culprit, Treatment Target, or Possible Biomarker? International Journal of Clinical Reviews. doi: 10.5275/ijcr.2011.07.05
Young, H., Weidmann, A., Crawshaw, A., Byrne, E. (2013). Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology, 233. doi: 10.2147/ccid.s35312
Olisova, O. Ju., Kochergin, N. G., Vertieva, E. Ju. (2013). Androgeneticheskaja alopecija. Rossijskij zhurnal kozhnyh i venericheskih boleznej, 3, 53–57.
Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature, 438 (7070), 932–936. doi: 10.1038/nature04478
Ibragimov, O. D. (2008). Patomorfologicheskie pokazateli proliferativnoj aktivnosti kozhi u bol'nyh psoriazom. Novosti dermatovenerologii i reproduktivnogo zdorov'ja, 4, 87–92.
Kuroda, K., Sapadin, A., Shoji, T., Fleischmajer, R., Lebwohl, M. (2001). Altered Expression of Angiopoietins and Tie2 Endothelium Receptor in Psoriasis. Journal of Investigative Dermatology, 116 (5), 713–720. doi: 10.1046/j.1523-1747.2001.01316.x
Walsh, D. A. (2007). Pathophysiological Mechanisms of Angiogenesis. Advances in Clinical Chemistry, 187–221. doi: 10.1016/s0065-2423(07)44006-9
Tolmacheva, N. V., Anisimova, A. S. (2015). Sovremennyj vzgljad na jetiologiju i patogenez psoriaza. Fundamental'nye issledovanija, 1, 2118–2121.
Raut, A. S., Prabhu, R. H., Patravale, V. B. (2013). Psoriasis Clinical Implications and Treatment: A Review. Critical Reviews in Therapeutic Drug Carrier Systems, 30 (3), 183–216. doi: 10.1615/critrevtherdrugcarriersyst.2013005268
Smol'nikova, N. V., Smirnova, S. V., Barilo, A. A. (2015). Osobennosti immunopatogeneza psoriaza i psoriaticheskogo artrita. Fundamental'nye issledovanija, 1-7, 1443–1447.
Ajvazova, T. V., Kushlinskij, N. E., Perlamutrov, Ju. N. (2008). Osobennosti angiogeneza bol'nyh jekssudativnoj formoj psoriaza. Klinicheskaja dermatologija i venerologija, 3, 8–11.
Marina, M. E., Roman, I. I., Constantin, A.-M., Mihu, C. M., Tătaru, A. D. (2015). VEGF involvement in psoriasis. Clujul Medical, 88 (3), 247. doi: 10.15386/cjmed-494
Namazova, L. S., Mazitova, L. P., Murashkin, N. N. (2009). Osobennosti angiogeneza i obosnovanie patogeneticheskoj terapii u detej, stradajushhih psoriazom. Vestnik dermatologii i venerologii, 1, 81–87.
Detmar, M. (2004). Evidence for Vascular Endothelial Growth Factor (VEGF) as a Modifier Gene in Psoriasis. Journal of Investigative Dermatology, 122 (1), xiv–xv. doi: 10.1046/j.0022-202x.2003.22140.x
Young, H. S., Bhushan, M., Griffiths, C. E. M., Summers, A. M., Brenchley, P. E. C. (2004). Single-Nucleotide Polymorphisms of Vascular Endothelial Growth Factor in Psoriasis of Early Onset. Journal of Investigative Dermatology, 122 (1), 209–215. doi: 10.1046/j.0022-202x.2003.22107.x
Markham, T., Mullan, R., Golden-Mason, L., Rogers, S., Bresnihan, B., FitzGerald, O. et. al (2006). Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. Journal of the American Academy of Dermatology, 54 (6), 1003–1012. doi: 10.1016/j.jaad.2006.01.038
Creamer, D., Allen, M., Jaggar, R., Stevens, R., Bicknell, R., Barker, J. (2002). Mediation of Systemic Vascular Hyperpermeability in Severe Psoriasis by Circulating Vascular Endothelial Growth Factor. Archives of Dermatology, 138 (6). doi: 10.1001/archderm.138.6.791
Carmeliet, P., Jain, R. K. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature, 473 (7347), 298–307. doi: 10.1038/nature10144
Forough, R. (2006). New frontiers in angiogenesis. Netherlands: Springer, 205. doi: 10.1007/1-4020-4327-9
Moens, S., Goveia, J., Stapor, P. C., Cantelmo, A. R., Carmeliet, P. (2014). The multifaceted activity of VEGF in angiogenesis – Implications for therapy responses. Cytokine & Growth Factor Reviews, 25 (4), 473–482. doi: 10.1016/j.cytogfr.2014.07.009
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Людмила Анатольевна Болотная, Елена Игоревна Сариан, Анна Александровна Лопандина
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
